Dr. Zhou has multi-discipline expertise from both academic and industrial background with over 20 years’ experience in drug discovery and development and he founded Danatlas Pharmaceuticals as Chairman and CEO in 2021. From 2015 to 2021, he served as SVP and CBO at Jacobio Pharmaceuticals, managing more than 10 R&D pipelines. Notably, he also directed the landmark licensing of SHP2 inhibitor program to AbbVie and co-led its advancement into Phase II trials as a JSC key member. Earlier at Novartis Oncology (2009-2015) as Lab Head, he successfully led several first-in-class small molecules and siRNA programs from target discovery to Phase I studies. He holds a Ph.D. in Molecular Biology from the University of Melbourne and completed postdoctoral training at UC San Diego School of Medicine, trained under internationally renowned scientist Michael G. Rosenfeld, a dual-elected member of the US National Academy of Sciences and National Academy of Medicine.